American Liver Foundation Statement on FDA Approval of Resmetirom

A press release today stated in part:

"Today, the Food and Drug Administration (FDA) granted accelerated approval of a first of its kind drug therapy, resmetirom, for the treatment of nonalcoholic steatohepatitis (NASH) in patients who have progressed to fibrosis. NASH, now called metabolic dysfunction-associated steatohepatitis or MASH, is a dangerously progressive form of nonalcoholic fatty liver disease* (NAFLD) and causes inflammation in the liver and liver damage."

This is great news!

For the full article, here is the link.

https://liverfoundation.org/resource-center/blog/american-liver-foundation-statement-on-fda-approval

Love, Sue

#healprydeliver #cirrhosis #NASH #MASH #NAFLD #MAFLD #americanliverfoundation